Table 3 Correlation between HNPs and clinical parameters in patients with myositis-associated ILD
HNPs in plasma | HNPs in BALF | |||||||
|---|---|---|---|---|---|---|---|---|
N | r | 95% CI | q-value | N | r | 95% CI | q-value | |
Laboratory data | ||||||||
CK (IU/L) | 55 | 0.135 | −0.135–0.387 | 1.00 | 43 | 0.029 | −0.274–0.327 | 0.92 |
PaO2 (torr) | 28 | −0.062 | −0.425–0.318 | 1.00 | 35 | 0.182 | − 0.161–0.486 | 0.49 |
KL-6 (U/mL) | 53 | − 0.122 | − 0.380–0.153 | 1.00 | 41 | 0.267 | −0.044–0.531 | 0.23 |
SP-D (ng/mL) | 49 | 0.029 | − 0.254–0.308 | 1.00 | 38 | 0.205 | −0.123–0.492 | 0.41 |
SP-A (ng/mL) | 44 | 0.010 | −0.288–0.306 | 0.95 | 29 | 0.528 | 0.200–0.750 | 0.02 |
Pulmonary function test | ||||||||
%VC (%) | 40 | −0.023 | −0.332–0.291 | 1.00 | 34 | −0.048 | −0.380–0.295 | 0.93 |
%DLco (%) | 40 | −0.071 | −0.374–0.246 | 1.00 | 34 | −0.017 | −0.353–0.323 | 0.92 |
BALF cell findings | ||||||||
TCC (×105/mL) | 45 | 0.409 | 0.131–0.627 | 0.07 | 44 | 0.147 | −0.157–0.425 | 0.49 |
Lymphocytes (%) | 45 | −0.013 | −0.305–0.282 | 1.00 | 44 | −0.305 | −0.552–0.009 | 0.17 |
Neutrophils (%) | 45 | 0.266 | −0.030–0.519 | 0.52 | 44 | 0.693 | 0.499–0.821 | 0.01 |
HRCT findings | ||||||||
Ground glass opacity (%) | 52 | 0.132 | −0.146–0.391 | 1.00 | 41 | 0.102 | −0.212–0.397 | 0.69 |
Consolidation (%) | 52 | 0.095 | −0.183–0.359 | 1.00 | 41 | −0.237 | −0.508–0.076 | 0.30 |
Reticular opacities (%) | 52 | −0.028 | −0.299–0.247 | 1.00 | 41 | 0.284 | −0.026–0.544 | 0.23 |